Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas increased its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 18.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,769 shares of the company’s stock after acquiring an additional 3,585 shares during the period. Teacher Retirement System of Texas’ holdings in Syndax Pharmaceuticals were worth $301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNDX. E Fund Management Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 14.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock worth $167,000 after purchasing an additional 1,583 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock worth $239,000 after buying an additional 1,732 shares during the period. R Squared Ltd purchased a new position in Syndax Pharmaceuticals during the 4th quarter worth approximately $26,000. Y Intercept Hong Kong Ltd lifted its stake in Syndax Pharmaceuticals by 2.5% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company’s stock valued at $1,101,000 after acquiring an additional 1,995 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at $49,000.

Syndax Pharmaceuticals Trading Down 2.2 %

Shares of SNDX stock opened at $12.01 on Wednesday. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.63 and a 12-month high of $25.07. The business’s 50 day moving average is $14.25 and its two-hundred day moving average is $15.77. The company has a market capitalization of $1.03 billion, a P/E ratio of -3.31 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.32 million. On average, research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on SNDX shares. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research note on Wednesday. Scotiabank lowered their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Citigroup decreased their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.20.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock valued at $336,087 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).